Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five‐drug dose conversion table

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Movement Disorders

• Publication date

  2004-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/mds.20210PMID 15389984
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Valvular heart disease in patients taking pergolide.

  2005cited by this paper
• Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide

  2003cited by this paper
• Sexually transmitted diseases treatment guidelines

  2003cited by this paper
• Valvular heart disease in patients taking pergolide.

  2002cited by this paper
• Long-term studies of dopamine agonists

  2002cited by this paper
• Switching from Bromocriptine to Ropinirole in Patients with Advanced Parkinson's Disease: Open Label Pilot Responses to Three Different Dose-Ratios

  2001cited by this paper
• Switching from pergolide to pramipexole in patients with Parkinson's disease

  2001cited by this paper
• Neurosyphilis presenting as progressive supranuclear palsy

  2000cited by this paper
• A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

  2000cited by this paper
• Neurosyphilis as a cause of facial and vestibulocochlear nerve dysfunction: MR imaging features.

  2000cited by this paper
• Cognitive and MRI aspects of corticobasal degeneration and progressive supranuclear palsy.

  2000cited by this paper
• Relationship between MRI findings and prognosis for patients with general paresis.

  2000cited by this paper
• Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

  2000cited by this paper
• Ropinirole and Pramipexole, the New Agonists

  1999cited by this paper
• Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide

  1999cited by this paper
• Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.

  1999cited by this paper
• An overnight switch to ropinirole therapy in patients with Parkinson's disease

  1999cited by this paper
• Switching dopamine agonists in advanced Parkinson’s disease

  1999cited by this paper
• Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease.

  1998cited by this paper
• Neurosyphilis in patients with AIDS.

  1997cited by this paper
• Syphilis serology in human immunodeficiency virus infection: evidence for false-negative fluorescent treponemal testing.

  1997cited by this paper
• Cabergoline in Parkinson's disease complicated by motor fluctuations

  1996cited by this paper
• [Drug-induced pleurisy].

  1996cited by this paper
• Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide.

  1995cited by this paper
• [Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease].

  1995cited by this paper
• Corticobasal degeneration: A clinical study of 36 cases

  1994cited by this paper
• [Pleural effusion and constrictive pericarditis secondary to bromocriptine treatment].

  1991cited by this paper
• Parkinson's Disease and Movement Disorders

  1990cited by this paper
• Retroperitoneal fibrosis in two patients with Parkinson's disease treated with bromocriptine.

  1990cited by this paper
• Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease.

  1990cited by this paper
• Agonist substitution in advanced Parkinson's disease

  1989cited by this paper
• Clinical significance of cerebrospinal fluid tests for neurosyphilis

  1989cited by this paper
• Immunological diagnosis of sexually transmitted diseases

  1988cited by this paper
• Chronic syphilitic meningitis resulting in superior orbital fissure syndrome and posterior fossa gumma. A report of two cases followed for 20 years.

  1988cited by this paper
• Parkinson's Disease of Post‐eneephalitic Type Following General Paresis:— An Autopsied Case —

  1983cited by this paper
• Parkinsonism secondary to neurosyphilis. A case report.

  1983cited by this paper

• Electrophysiological and biochemical evaluations of neuropathy risk in oral levodopa versus levodopa/carbidopa intestinal gel treatment

  2025cites this paper
• A Comparison of Short and Long-Term Acting Dopamine Agonists in the Treatment of Parkinson’s Disease with Respect to the Side Effects of Impulse Control Disorder

  2025cites this paper
• Associations between gut microbiota characteristics and non‐motor symptoms following pharmacological and surgical treatments in Parkinson's disease patients

  2024cites this paper
• Relationship between motor learning and gambling propensity in Parkinson’s disease

  2022cites this paper
• Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease.

  2022cites this paper
• Emergency presentations of movement disorders

  2020cites this paper
• Mythology of Parkinson’s disease: from levodopa phobia to dopamine agonist phobia

  2020cites this paper
• Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey

  2020cites this paper
• Parkinson’s disease management and impulse control disorders: current state and future perspectives

  2019cites this paper
• The relationship between temperament and depression in Parkinson's disease patients under dopaminergic treatment

  2018cites this paper
• Changes in cortical excitability during paired associative stimulation in Parkinson's disease patients and healthy subjects.

  2017cites this paper
• Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy

  2017cites this paper
• Subthalamic Nucleus Deep Brain Stimulation Alters Prefrontal Correlates of Emotion Induction

  2017cites this paper
• Apomorphine pump in advanced Parkinson's disease: Effects on motor and nonmotor symptoms with brain metabolism correlations.

  2017cites this paper
• [Safinamide from daily clinical practice: first clinical steps].

  2017cites this paper
• Recommendations for the Treatment of Patients With Parkinson Disease During Ramadan

  2017cites this paper
• Minor hallucinations occur in drug‐naive Parkinson's disease patients, even from the premotor phase

  2016cites this paper
• Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment

  2016cites this paper
• A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short‐ and long‐acting dopamine agonists

  2016cites this paper
• Erratum to: Effects of Global Postural Reeducation on gait kinematics in parkinsonian patients: a pilot randomized three-dimensional motion analysis study

  2016cites this paper
• The Effect of Medical Theraphy On Plasma Homocysteine Levels and Carotid Intima-media Thickness in Parkinson's Disease

  2016cites this paper
• Symptom Severity of Restless Legs Syndrome Predicts Its Clinical Course.

  2016cites this paper
• Stimulation sites in the subthalamic nucleus and clinical improvement in Parkinson's disease: a new approach for active contact localization.

  2016cites this paper
• Chapitre 13 – Stratégies médicamenteuses

  2015cites this paper
• Prolactin and sex hormones levels in males with Parkinson's disease

  2015cites this paper
• Effects of Global Postural Reeducation on gait kinematics in parkinsonian patients: a pilot randomized three-dimensional motion analysis study

  2015cites this paper
• Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease.

  2014cites this paper
• Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process.

  2014cites this paper
• Alpha and beta EEG power reflects L-dopa acute administration in parkinsonian patients

  2014influential citation
• Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study

  2014cites this paper
• Treatment of early Parkinson's disease.

  2014cites this paper
• [Drug treatment of early-stage (de novo and "honeymoon") Parkinson disease].

  2014cites this paper
• History of exposure to dopaminergic medication does not affect motor cortex plasticity and excitability in Parkinson's disease.

  2013influential citation
• Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease

  2013cites this paper
• Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude.

  2013cites this paper
• Clinical Characteristics with an Impact on ADL Functions of PD Patients with Cognitive Impairment Indicative of Dementia

  2013cites this paper
• Pattern of Regional Cortical Thinning Associated with Cognitive Deterioration in Parkinson’s Disease

  2013cites this paper
• High-frequency repetitive transcranial magnetic stimulation over the primary foot motor area in Parkinson's disease.

  2013cites this paper
• Uticaj transkranijalne magnetne stimulacije na kliničke znake i elektrofiziološke parametre kod obolelih od Parkinsonove bolesti

  2013cites this paper
• Cognitive Profiles in Parkinson's Disease and Their Relation to Dementia: A Data-Driven Approach

  2012cites this paper
• Hallucinations in Parkinson’s disease: cross-sectional study

  2012cites this paper
• Effect of Global Postural Rehabilitation program on spatiotemporal gait parameters of parkinsonian patients: a three-dimensional motion analysis study

  2012cites this paper
• The Role of Ghrelin, Neuropeptide Y and Leptin Peptides in Weight Gain after Deep Brain Stimulation for Parkinson’s Disease

  2012cites this paper
• Anti-cholinergics for axial symptoms in Parkinson's disease after subthalamic stimulation.

  2012cites this paper
• Spectroscopic Changes Associated with Mild Cognitive Impairment and Dementia in Parkinson’s Disease

  2012cites this paper
• The relationship between cerebral vascular disease and parkinsonism: The VADO study.

  2012cites this paper
• The impact of silent vascular brain burden in cognitive impairment in Parkinson’s disease

  2012cites this paper
• Chapitre 12 – Stratégies médicamenteuses antiparkinsoniennes

  2011cites this paper
• Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease.

  2011cites this paper
• Intertemporal choice in Parkinson's disease

  2011cites this paper
• Advanced magnetic resonance imaging in benign hereditary chorea: Study of two familial cases

  2010cites this paper
• PDD‐Short Screen: A brief cognitive test for screening dementia in Parkinson's disease

  2010cites this paper
• Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain‐to‐pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy

  2010cites this paper
• Lowered cardiac sympathetic nerve performance in response to exercise in Parkinson's disease

  2010cites this paper
• Adult cases of congenital muscular torticollis successfully treated with botulinum toxin

  2010cites this paper
• Early (Uncomplicated) Parkinson's Disease

  2010cites this paper
• Long‐term stability of effects of subthalamic stimulation in Parkinson's disease: Indian Experience

  2010cites this paper
• Olfactory dysfunction and cardiovascular dysautonomia in Parkinson’s disease

  2010cites this paper
• Slow (1 Hz) repetitive transcranial magnetic stimulation (rTMS) induces a sustained change in cortical excitability in patients with Parkinson's disease.

  2010cites this paper
• Long term follow-up of Parkinson's disease patients with impulse control disorders.

  2010cites this paper
• Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease

  2010cites this paper
• Parkinson's Disease and pathological gambling: Results from a functional MRI study

  2010cites this paper
• Fatigue in Parkinson's disease: Prevalence and associated factors

  2010cites this paper
• Dissociation between time reproduction of actions and of intervals in patients with Parkinson’s disease

  2010cites this paper
• CSF Aβ42 and tau in Parkinson's disease with cognitive impairment

  2010cites this paper
• Compulsive Behaviors in Patients With Parkinson's Disease

  2010cites this paper
• Asymptomatic Deep Venous Thrombosis after Deep Brain Stimulation for Parkinson Disease

  2010influential citation
• What is the functional significance of nondominant arm tremor in essential tremor?

  2010cites this paper
• Low-frequency repetitive transcranial magnetic stimulation and off-phase motor symptoms in Parkinson's disease.

  2010cites this paper
• The Parkinsonism-Hyperpyrexia Syndrome

  2009influential citation
• An open‐label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease

  2009cites this paper
• Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan.

  2009influential citation
• Slow wave sleep and dopaminergic treatment in Parkinson’s disease: a polysomnographic study

  2009cites this paper
• Treatment of Early Parkinson’s Disease

  2009cites this paper
• Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review

  2009influential citation
• The relation of testosterone levels with fatigue and apathy in Parkinson's disease.

  2009cites this paper
• Prevalence and diagnosis of Parkinson's disease : a community study.

  2009cites this paper
• On the role of dopamine replacement therapy in decision-making, working memory, and reward in Parkinson's disease: does the therapy-dose matter?

  2009cites this paper
• Neuro-psychiatric therapy during chronic subthalamic stimulation in Parkinson's disease.

  2009cites this paper
• Conversion From Dopamine Agonists to Cabergoline: An Open-Label Trial in 128 Patients With Advanced Parkinson Disease

  2008cites this paper
• Parkinson's disease‐cognitive rating scale: A new cognitive scale specific for Parkinson's disease

  2008cites this paper
• Pramipexole Safely Replaces Ergot Dopamine Agonists with either Rapid or Slow Switching

  2008cites this paper
• Motor changes during sertraline treatment in depressed patients with Parkinson’s disease *

  2008cites this paper
• The frequency of cardiac valvular regurgitation in Parkinson's disease

  2008cites this paper
• Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson’s disease

  2007cites this paper
• [Choosing a dopamine agonist in Parkinson's disease].

  2007cites this paper
• Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome

  2007cites this paper
• Motor and Nonmotor Symptom Follow-Up in Parkinsonian Patients after Deep Brain Stimulation of the Subthalamic Nucleus

  2007cites this paper
• Controlled study of decision‐making and cognitive impairment in Parkinson's disease

  2007cites this paper
• Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.

  2007cites this paper
• Relationship between age and subtypes of psychotic symptoms in Parkinson's disease

  2007cites this paper
• Changes in quality of life in people with Parkinson’s disease left untreated at diagnosis

  2007cites this paper
• Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: an ECD-SPECT study.

  2007cites this paper
• [Prescription switch studies: objectives, methods and limits].

  2007cites this paper
• Extradural motor cortex stimulation in Parkinson's disease

  2007cites this paper
• Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.

  2007cites this paper
• Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.

  2007cites this paper
• Effects of unilateral subthalamic deep brain stimulation on contralateral arm sequential movements in Parkinson’s disease

  2007cites this paper
• Pharmacotherapy and Treatment of Parkinson's Disease

  2007cites this paper
• Étude des reports de prescription : objectifs, méthodes et limites

  2007cites this paper